These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
456 related articles for article (PubMed ID: 29119148)
61. Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer. Straughan DM; Azoury SC; Shukla V Curr Drug Targets; 2016; 17(6):739-45. PubMed ID: 26073862 [TBL] [Abstract][Full Text] [Related]
62. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. Ignatius Ou SH; Azada M; Hsiang DJ; Herman JM; Kain TS; Siwak-Tapp C; Casey C; He J; Ali SM; Klempner SJ; Miller VA J Thorac Oncol; 2014 Apr; 9(4):549-53. PubMed ID: 24736079 [TBL] [Abstract][Full Text] [Related]
63. New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer. Cameron L; Solomon B Curr Treat Options Oncol; 2015 Oct; 16(10):49. PubMed ID: 26318457 [TBL] [Abstract][Full Text] [Related]
64. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients. Dikopf A; Wood K; Salgia R Expert Opin Drug Saf; 2015 Mar; 14(3):485-93. PubMed ID: 25659177 [TBL] [Abstract][Full Text] [Related]
65. Crizotinib for the treatment of patients with advanced non-small cell lung cancer. Bowles DW; Weickhardt AJ; Doebele RC; Camidge DR; Jimeno A Drugs Today (Barc); 2012 Apr; 48(4):271-82. PubMed ID: 22536569 [TBL] [Abstract][Full Text] [Related]
66. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538 [TBL] [Abstract][Full Text] [Related]
67. Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. Caccese M; Ferrara R; Pilotto S; Carbognin L; Grizzi G; Caliò A; Brunelli M; Cuppone F; Petraglia S; Scarpa A; Tortora G; Bria E Expert Opin Pharmacother; 2016 Dec; 17(17):2253-2266. PubMed ID: 27682212 [TBL] [Abstract][Full Text] [Related]
68. The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer. Kaczmar J; Mehra R Ther Adv Respir Dis; 2015 Oct; 9(5):236-41. PubMed ID: 26229087 [TBL] [Abstract][Full Text] [Related]
69. [Modalities of use of ceritinib (Zykadia™), a 2nd generation ALK inhibitor, in advanced stage non-small cell lung cancer]. Giroux Leprieur E; Fallet V; Wislez M Bull Cancer; 2015 Dec; 102(12):1053-7. PubMed ID: 26597476 [TBL] [Abstract][Full Text] [Related]
70. [Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer]. Giroux Leprieur E; Wislez M Bull Cancer; 2016 Feb; 103(2):125-6. PubMed ID: 26822904 [No Abstract] [Full Text] [Related]